Effect of Prefilled vs Vial-Drawn Syringes on Sustained Increases in Intraocular Pressure in Patients Treated With Aflibercept.
J Vitreoretin Dis
; 7(6): 498-503, 2023.
Article
em En
| MEDLINE
| ID: mdl-37974923
ABSTRACT
Purpose:
To evaluate the effect of syringe type on developing sustained intraocular pressure (IOP) increases.Methods:
This retrospective cohort study included patients in a single academic center receiving antivascular endothelial growth factor (anti-VEGF) injections from 2012 to 2022 for various indications. Patients were grouped by anti-VEGF treatment of either vial-drawn or prefilled syringe delivery. Trends in IOP were recorded for 1 year after treatment began. Development of sustained IOP increase, ocular hypertension, and glaucoma was recorded. Sustained IOP increase was defined as ≥5 mm Hg above baseline for at least 4 weeks.Results:
Of 257 total patients, 6 (2.3%) developed sustained IOP increases throughout the study's duration. No significant differences were noted with respect to prefilled versus vial-drawn syringe status on the development of sustained IOP increases or incident glaucoma (IOP 1.8% vs 2.7%, respectively, P = .65; glaucoma 0.0% vs 2.0%, respectively, P = .14). Patients treated with prefilled syringes were significantly less likely to develop ocular hypertension (2.8% vs 8.8%, P < .05).Conclusions:
This study found that aflibercept intravitreal injection with prefilled syringes was not associated with a significant increase in IOP-related adverse effects when compared with those treated with vial-drawn syringes.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
J Vitreoretin Dis
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos